NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free EXAI Stock Alerts $4.18 -0.20 (-4.57%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$4.13▼$4.4050-Day Range$4.24▼$7.1252-Week Range$4.13▼$9.12Volume246,701 shsAverage Volume700,685 shsMarket Capitalization$505.32 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Exscientia alerts: Email Address Exscientia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside133.8% Upside$9.75 Price TargetShort InterestBearish3.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector704th out of 909 stocksBiological Products, Except Diagnostic Industry121st out of 156 stocks 3.3 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.70% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Exscientia has recently increased by 15.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 2.3 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Exscientia this week, compared to 2 articles on an average week.Search InterestOnly 15 people have searched for EXAI on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows31 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is an increase of 15% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to grow in the coming year, from ($1.76) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Exscientia Stock (NASDAQ:EXAI)Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesApril 23, 2024 | americanbankingnews.comExscientia (NASDAQ:EXAI) Given "Equal Weight" Rating at Morgan StanleyApril 21, 2024 | americanbankingnews.comExscientia (NASDAQ:EXAI) Shares Down 5% April 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 18, 2024 | americanbankingnews.comExscientia (NASDAQ:EXAI) Sets New 52-Week Low at $4.17April 16, 2024 | finance.yahoo.comExscientia plc (EXAI) Interactive Stock Chart - Yahoo FinanceMarch 23, 2024 | seekingalpha.comExscientia plc (EXAI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | investorplace.comEXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q4 2023March 21, 2024 | businesswire.comExscientia Business and Financial Update for the Full Year 2023April 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | finance.yahoo.comExscientia plc's (NASDAQ:EXAI) market cap touched US$797m last week, benefiting both individual investors who own 48% as well as institutionsMarch 14, 2024 | ca.finance.yahoo.comEXAI Jul 2024 10.000 putMarch 14, 2024 | ca.finance.yahoo.comEXAI May 2024 2.500 putMarch 14, 2024 | ca.finance.yahoo.comEXAI Jul 2024 2.500 callMarch 14, 2024 | businesswire.comExscientia to Report Full Year 2023 Financial Results on March 21, 2024March 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAIMarch 4, 2024 | investorplace.comThe Top 3 Healthcare Stocks to Buy on Weakness in 2024March 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAIMarch 1, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Exscientia plc (EXAI) InvestorsFebruary 28, 2024 | businesswire.comExscientia to Present at Upcoming Investor Conferences in MarchFebruary 26, 2024 | businesswire.comExscientia plc (EXAI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAIFebruary 23, 2024 | finance.yahoo.comEXAI May 2024 17.500 callFebruary 23, 2024 | fool.comExscientia Plc (NASDAQ: EXAI)February 17, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAIFebruary 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAIFebruary 14, 2024 | msn.comOxford drug company sacks chief executive over ‘inappropriate’ relationships with staffFebruary 13, 2024 | msn.comExscientia CEO terminated from position due to inappropriate conduct - filingSee More Headlines Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/24/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees483Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+122.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-737.10% Pretax Margin-807.26% Return on Equity-36.44% Return on Assets-26.39% Debt Debt-to-Equity Ratio0.05 Current Ratio6.22 Quick Ratio6.22 Sales & Book Value Annual Sales$25.60 million Price / Sales20.68 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.20Miscellaneous Outstanding Shares120,890,000Free FloatN/AMarket Cap$529.50 million OptionableOptionable Beta0.78 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. David Hallett Ph.D. (Age 55)Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director Mr. Ben R. Taylor (Age 47)CFO, Chief Strategy Officer & Executive Director Comp: $524.4kDr. Michael Krams M.D. (Age 63)Chief Medical Officer Ms. Eileen Jennings-BrownChief Information OfficerMs. Sara ShermanVice President of Investor RelationsMr. Dan IrelandVice President of Legal & Company SecretaryMr. Parker MossExecutive Vice President of Corporate DevelopmentMs. Caroline RowlandChief People OfficerMr. Richard LawChief Business OfficerDr. John P. Overington Ph.D.Chief Data OfficerMore ExecutivesKey CompetitorsValnevaNASDAQ:VALNFate TherapeuticsNASDAQ:FATEAlectorNASDAQ:ALECAllogene TherapeuticsNASDAQ:ALLOPrime MedicineNYSE:PRMEView All CompetitorsInstitutional OwnershipGAMMA Investing LLCBought 2,302 shares on 4/5/2024Ownership: 0.004%Platinum Investment Management Ltd.Sold 306,740 shares on 2/14/2024Ownership: 3.382%Walled Lake Planning & Wealth Management LLCBought 10,000 shares on 2/13/2024Ownership: 0.008%Tower Research Capital LLC TRC Sold 1,926 shares on 2/13/2024Ownership: 0.003%New Republic Capital LLCBought 20,000 shares on 2/12/2024Ownership: 0.017%View All Institutional Transactions EXAI Stock Analysis - Frequently Asked Questions Should I buy or sell Exscientia stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAI shares. View EXAI analyst ratings or view top-rated stocks. What is Exscientia's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for Exscientia's shares. Their EXAI share price targets range from $7.00 to $13.00. On average, they predict the company's stock price to reach $9.75 in the next twelve months. This suggests a possible upside of 133.8% from the stock's current price. View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts. How have EXAI shares performed in 2024? Exscientia's stock was trading at $6.41 at the start of the year. Since then, EXAI stock has decreased by 34.9% and is now trading at $4.17. View the best growth stocks for 2024 here. When is Exscientia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our EXAI earnings forecast. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative trailing twelve-month return on equity of 36.44%. What ETF holds Exscientia's stock? First Trust Nasdaq Artificial Intelligence and Robotics ETF holds 1,432,035 shares of EXAI stock, representing 1.28% of its portfolio. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. Who are Exscientia's major shareholders? Exscientia's stock is owned by a variety of institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EXAI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry Research"The Biggest Drug Ever" Is ComingBehind the MarketsNew Trump BombshellThe Freeport SocietyMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
